MedPath

YONDELIS

These highlights do not include all the information needed to use YONDELIS safely and effectively. See full prescribing information for YONDELIS. YONDELIS (trabectedin) for injection, for intravenous useInitial U.S. Approval: 2015

Approved
Approval ID

472bd78e-be17-4b9d-90f4-9482c3aec9ff

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 22, 2020

Manufacturers
FDA

Janssen Products, LP

DUNS: 804684207

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Trabectedin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code59676-610
Application NumberNDA207953
Product Classification
M
Marketing Category
C73594
G
Generic Name
Trabectedin
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateDecember 31, 2018
FDA Product Classification

INGREDIENTS (5)

TrabectedinActive
Quantity: 0.05 mg in 1 mL
Code: ID0YZQ2TCP
Classification: ACTIB
SucroseInactive
Code: C151H8M554
Classification: IACT
Potassium Phosphate, MonobasicInactive
Code: 4J9FJ0HL51
Classification: IACT
Potassium HydroxideInactive
Code: WZH3C48M4T
Classification: IACT
Phosphoric AcidInactive
Code: E4GA8884NN
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

YONDELIS - FDA Drug Approval Details